Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers

Changfeng Ji1,*, Qinglei Zhang1,*, Wenxian Guan2, Tingting Guo3, Ling Chen4, Song Liu1, Jian He1 and Zhengyang Zhou1

1Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China, 210008
2Department of Gastrointestinal Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China, 210008
3Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, 210008
4Department of Pathology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China, 210008

*These authors contributed equally to this work

Correspondence to: Song Liu, email: liusongnj@126.com
Jian He, email: hjxueren@126.com
Zhengyang Zhou, email: zyzhou@nju.edu.cn

Keywords: intravoxel incoherent motion, magnetic resonance imaging, stomach neoplasm, human epidermal growth factor receptor 2, immunohistochemistry

ABSTRACT

Purpose: To explore the role of intravoxel incoherent motion (IVIM) magnetic resonance (MR) imaging in evaluating human epidermal growth factor receptor 2 (HER2) status of gastric cancers preoperatively.

Results: The apparent diffusion coefficient (ADC) and pure diffusion coefficient (D) values correlated positively with HER2 scores of gastric cancers significantly (r = 0.276, P = 0.048; r = 0.481, P < 0.001, respectively). The ADC and D values of HER2 positive gastric cancers were significantly higher than those of HER2 negative tumors (P = 0.033, 0.007, respectively). With a cut-off value of 1.321 and 1.123 × 10⁻³ mm²/sec, the ADC and D values could distinguish HER2 positive gastric cancers from HER2 negative ones with an area under the curve of 0.733 and 0.762, respectively (P = 0.023, 0.011, respectively).

Materials and methods: Fifty-three patients with gastric cancers underwent IVIM MR imaging preoperatively. The values of ADC, D, pseudo diffusion coefficient (D*) and perfusion related fraction (f) of the lesions were obtained. Partial correlation test including tumor volume was performed to analyze correlations between IVIM values and HER2 scores excluding the impact of tumor size. IVIM parameters of gastric cancers with different HER2 status were compared using independent samples t test. Diagnostic performance of IVIM parameters in distinguishing HER2 positive gastric cancers from negative ones was tested with receiver operating characteristic analysis.

Conclusions: We confirmed the feasibility of IVIM MR imaging in preoperative assessment of HER2 status of gastric cancers, which might make up the shortfall of biopsy and facilitate personalized treatment for patients with gastric cancers.

INTRODUCTION

Gastric cancer is one of the most common digestive malignancies worldwide and many patients were diagnosed at advanced stage [1]. Since traditional chemotherapy often encountered resistance with a number of side effects, molecular targeted therapy became another choice for selected patients [2, 3]. Human epidermal growth factor receptor 2 (HER2) is a proto-oncogene encoded by ERBB2 on chromosome...
17. When the amplification of HER2 gene occurs, it induces the overexpression of HER2 protein. Then an excessive amount of HER2-containing heterodimers will be formed which enhances the signaling responses to growth factors. With a complex signaling network, the overexpression of HER2 leads to activations associated with cell proliferation, differentiation and survival [4–6]. And HER2 overexpression is an important biomarker for treatment with trastuzumab in patients with gastric and gastroesophageal junction cancers [3]. ToGA trial indicated that the combination of chemotherapy plus trastuzumab proved superior to chemotherapy alone with an extend survival from 11.8 to 16.0 months among patients with higher HER2 expression [3]. Hence, an accurate assessment of HER2 status is critical to optimize the therapeutic effect.

Nowadays, the information of HER2 status is mainly obtained through immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) using biopsy or surgical specimens. However, patients diagnosed at advanced stage usually lose their chance of surgical resection, and endoscopic biopsy can only be used, which is unable to avoid sampling error. In cases with smaller areas of HER2 expression, a biopsy sample taken from a negative area would return a false negative result [7].

During the past few years, magnetic resonance (MR) imaging has been increasingly utilized in preoperative evaluation of gastric cancers [8–10]. Especially diffusion weighted (DW) imaging showed great potential in detection, differentiating diagnosis and features characterization of gastric cancers [11–13]. For instance, the apparent diffusion coefficient (ADC) value correlated significantly with histological differentiation, Lauren classification and TNM staging of gastric cancers [14–16]. Moreover, one previous study reported that the mean and minimal ADC values of HER2 positive gastric cancers were significantly higher than those of HER2 negative ones [17].

However, ADC values derived from traditional DW imaging using 2 b values reflect a combined effect of water molecular diffusion and microvascular perfusion [18]. As an extend model based on DW imaging, intravoxel incoherent motion (IVIM) is able to separate diffusion from perfusion component in vivo using an increased number of b values [19]. MR signals obtained at higher b values are mainly related to diffusion, while perfusion effects display dominance at lower b values [20]. With a bi-exponential decay model, the pure diffusion coefficient (D) and pseudo diffusion coefficient (D*) could be obtained simultaneously, along with perfusion related fraction (f). Since its first introduction in 1986 [21], IVIM MR imaging has shown a great potential in characterizing and grading various tumors. For instance, values of IVIM-derived parameters were significantly correlated with histological grade of hepatocellular carcinoma (HCC), and they showed significance in differentiating high-grade from low-grade HCC [22]. Kim Y et al detected significantly lower ADC and D values in HER2 negative breast cancer than positive ones [23]. We hypothesized that IVIM parameters might change based on different HER2 status of gastric cancer, which has never been reported previously.

Therefore, the purpose of this study was to compare the IVIM parameters between HER2 positive and negative gastric cancers, and to explore the role of IVIM MR imaging in evaluating HER2 status of gastric cancers preoperatively.

RESULTS

From Nov. 2015 to Oct. 2016, a total of 53 patients with gastric cancers were prospectively enrolled in this study. The patients comprised 32 men and 21 women (age range, 28 ~ 78 years; mean age ± standard deviation, 60 ± 10 years). A detailed inclusion and exclusion flowchart is shown in Figure 1.

The clinicopathological characteristics of the 53 patients with gastric cancers and different HER2 status are shown in Table 1. Each patient had one lesion identified.

There was significant difference of the D values among gastric cancers with different HER2 scores (P = 0.001) (Table 2), especially between score 0 and score 2+ (P < 0.001) (Figure 2). And the ADC and D values correlated positively with HER2 scores of gastric cancers significantly (r = 0.276, P = 0.048; r = 0.481, P < 0.001, respectively, with partial correlation test including tumor volume).

The ADC and D values of HER2 positive gastric cancers were significantly higher than those of HER2 negative tumors (P = 0.033, 0.007, respectively) (Table 2). With a cut-off value of 1.321 and 1.123 × 10⁻³ mm²/sec, the ADC and D values could distinguish HER2 positive gastric cancers from HER2 negative ones with an area under the curve (AUC) of 0.733 and 0.762, respectively (P = 0.023, 0.011, respectively) (Table 3, Figure 3). The representative cases of HER2 positive and negative gastric cancers are shown in Figures 4 and 5, respectively.

DISCUSSION

We successfully performed IVIM MR imaging in patients with gastric cancers, and found that preoperative IVIM parameters correlated with HER2 status based on postoperative specimens significantly, which has never been reported previously.

It was reported that HER2 positive gastric cancers were more frequently found in gastroesophageal junction, intestinal type and well differentiated cases [7, 24–28]. In our study, there were no significant differences of HER2 status among different age groups, genders, tumor locations, and differentiation degrees. Although it differed in Lauren classification, our data with only 53 patients was
not enough to verify the difference of HER2 positivity in different Lauren classifications. However, a group of studies with large sample size have demonstrated these differences. For instance, Aizawa M et al. reported that higher HER2 positivity was found in well or moderately differentiated gastric cancers than poorly differentiated ones (data from 1,006 patients) [28]. Van Cutsem E et al. reported that overexpression or amplification of HER2 was more common in patients with intestinal histology compared with those with diffuse histology (data from 3,665 patients) [24].

The ADC and D values are parameters reflecting the water molecule diffusion. We found that both ADC and D values correlated positively with HER2 scores of gastric cancers significantly. That is, as HER2 score of gastric cancers increased from 0 to 3+, the ADC and D values also increased gradually. And ADC and D values of HER2 positive gastric cancers were significantly higher than those of HER2 negative tumors, which was consistent with our previous study on traditional ADC values [17].

It was reported that HER2 overexpression tended to be found in well differentiated gastric cancers [28]. As the differentiation degree of gastric cancer decreases, the normal glandular structures are lost. The amount and density of tumor cells increases while their arrangement becomes disordered. A large cell volume and irregular cell shape cause narrower and more distorted intercellular space. As a result, the water molecule diffusion is limited. The loss of cell structure in well differentiated gastric cancers is relatively slight. Thus there are larger spaces for the motion of water molecules in well differentiated tumors, which might lead to higher ADC and D values [14]. A group of studies also reported that HER2 overexpression was more common in intestinal type gastric cancers [24, 29, 30]. Tubular or gland structures are commonly observed in the intestinal type, which may cause relatively large spaces for the motion of water molecules. As a result, intestinal type gastric cancers might show higher ADC and D values.

Moreover, IVIM-derived D value could reflect the motion of water molecules more factually than ADC value for excluding the impact of perfusion effect. Woo S et al. reported that ADC value showed a fair relationship with histologic grade of hepatocellular carcinoma ($r = -0.448$, $P = 0.002$), while $D$ value demonstrated a moderate to good relationship ($r = -0.604$, $P < 0.001$) with Spearman correlation test [31]. In our study, the correlation between the D value and HER2 scores ($r = 0.481$) was stronger than the ADC value ($r = 0.276$) with partial correlation test including tumor volume. And our previous study showed that the mean and minimal ADC values correlated with HER2 scores of gastric cancers with $r$ values of 0.419 and 0.367 (Spearman correlation test) [17], which were also weaker than the D value in the current study. Both ADC and D values

---

**Figure 1:** Inclusion and exclusion flowchart of this study.
Table 1: Clinicopathological information of patients with gastric cancers and different human epidermal growth factor receptor 2 (HER2) status

| Characteristics        | n    | HER2 (−) (%) | HER2 (+) (%) | P value |
|------------------------|------|--------------|--------------|---------|
| Gender                 |      |              |              |         |
| Male                   | 32   | 25 (78.1)    | 7 (21.9)     | 0.722   |
| Female                 | 21   | 18 (85.7)    | 3 (14.3)     |         |
| ≤ 60 years             | 22   | 19 (86.4)    | 3 (13.6)     | 0.494   |
| > 60 years             | 31   | 24 (77.4)    | 7 (22.6)     |         |
| Location               |      |              |              |         |
| Gastroesophageal junction | 17  | 12 (70.6)    | 5 (29.4)     | 0.260   |
| Other stomach          | 36   | 31 (86.1)    | 5 (13.9)     |         |
| Pathological type      |      |              |              |         |
| Ade                    | 38   | 29 (76.3)    | 9 (23.7)     |         |
| Pcc                    | 9    | 8 (88.9)     | 1 (11.1)     |         |
| Muc                    | 1    | 1 (100.0)    | 0 (0.0)      | 0.512   |
| Mixed                  | 5    | 5 (100.0)    | 0 (0.0)      |         |
| Poor                   | 34   | 29 (85.3)    | 5 (14.7)     |         |
| Differentiation degree |      |              |              |         |
| Moderate-poor          | 13   | 11 (84.6)    | 2 (15.4)     | 0.162   |
| Moderate               | 6    | 3 (50.0)     | 3 (50.0)     |         |
| Diffuse type           | 24   | 23 (95.8)    | 1 (4.2)      |         |
| Lauren classification  |      |              |              |         |
| Mixed type             | 14   | 10 (71.4)    | 4 (28.6)     | 0.046*  |
| Intestinal type        | 15   | 10 (66.7)    | 5 (33.3)     |         |
| T1                     | 2    | 1 (50.0)     | 1 (50.0)     |         |
| T2                     | 7    | 6 (85.7)     | 1 (14.3)     |         |
| T3                     | 33   | 26 (78.8)    | 7 (21.2)     | 0.565   |
| T4                     | 11   | 10 (90.9)    | 1 (9.1)      |         |
| N0                     | 6    | 5 (83.3)     | 1 (16.7)     |         |
| N1                     | 9    | 9 (100.0)    | 0 (0.0)      | 0.067   |
| N2                     | 15   | 9 (60.0)     | 6 (40.0)     |         |
| N3                     | 23   | 20 (87.0)    | 3 (13.0)     |         |
| M stage                |      |              |              |         |
| Mo                     | 50   | 40 (80.0)    | 10 (20.0)    | 0.615   |
| M1                     | 3    | 3 (100.0)    | 0 (0.0)      |         |

Note: Ade, tubular or papillary adenocarcinoma; Pcc, poorly cohesive carcinoma; Muc, mucinous carcinoma; Mixed, adenocarcinoma + poorly cohesive carcinoma (2 cases), poorly cohesive carcinoma + mucinous carcinoma (2 cases), adenocarcinoma + mucinous carcinoma (1 case). *P < 0.05 with chi square test.

Table 2: Intravoxel incoherent motion magnetic resonance parameters in gastric cancers with different human epidermal growth factor receptor 2 (HER2) scores and status

| HER2               | ADC  | D       | f       | D*      |
|--------------------|------|---------|---------|---------|
| Score 0 (n = 21)   | 1.245 ± 0.259 | 0.939 ± 0.186 | 0.201 ± 0.092 | 42.404 ± 44.215 |
| Score 1+ (n = 19)  | 1.257 ± 0.251 | 1.037 ± 0.186 | 0.141 ± 0.079 | 24.244 ± 14.465 |
| Score 2+ (n = 10)  | 1.452 ± 0.234 | 1.254 ± 0.194 | 0.149 ± 0.066 | 59.443 ± 34.492 |
| Score 3+ (n = 3)   | 1.455 ± 0.177 | 1.173 ± 0.285 | 0.165 ± 0.093 | 36.822 ± 40.510 |
| ANOVA              | P = 0.104 | P = 0.001† | P = 0.133 | P = 0.074 |
| Negative (n = 43)  | 1.264 ± 0.254 | 1.008 ± 0.208 | 0.168 ± 0.089 | 34.916 ± 33.486 |
| Positive (n = 10)  | 1.455 ± 0.218 | 1.212 ± 0.207 | 0.166 ± 0.073 | 55.461 ± 40.697 |
| t test             | P = 0.033‡ | P = 0.007‡ | P = 0.959 | P = 0.099 |

Note: ADC, apparent diffusion coefficient; D, pure diffusion coefficient; f, perfusion related fraction; D*, pseudo diffusion coefficient. The ADC, D and D* values are in unit of $\times 10^{-3}$ mm$^2$/sec. †P < 0.05 with one-way analysis of variance (ANOVA). ‡P < 0.05 with independent samples t test.
performed well in differentiating HER2 positive and negative gastric cancers with an AUC up to 0.733 and 0.762.

The f value reflects the vascular volume fraction of the tumor, and the D* value reflects the rate of microcapillary blood flow. Both of them represent the perfusion effect, while ADC and D values represent the diffusion effect of tissues [21]. We failed to detect any significant correlation between f or D* value and HER2 scores of gastric cancers in this study. Kim Y et al also reported no significant differences of f and D* values between HER2 positive and HER2 negative breast cancers, while there were significant differences of ADC and D values between them [23]. Ma L et al reported that dynamic contrast enhancement (DCE) MR derived Ve value of gastric cancers with diffuse type was significantly higher than those with intestinal type [32]. However, DCE or perfusion parameters did not necessarily correspond to f value. And the application of D* value was limited due to its instability and low signal to noise ratio [33, 34].

There were some limitations in our study. Firstly, the sample size was relatively small, especially for the cases with HER2 score 3+, which might cause some bias. Secondly, the pathologic foundation and mechanism of higher ADC and D values in HER2 positive gastric cancers were only speculative, without any standard reference. Thirdly, the number and setting of b values were arbitrarily chosen for IVIM imaging without optimization, and the region of interest (ROI) was drawn manually without the reference to postoperative specimen. All the issues would be investigated in our future work.

In conclusion, we confirmed the feasibility of IVIM MR imaging in preoperative assessment of HER2 status of gastric cancers in this study. We established correlations between the ADC as well as D values and HER2 scores of gastric cancers. IVIM MR derived parameters could serve as new biomarkers in predicting HER2 status of gastric cancers, which might make up the shortfall of biopsy and facilitate personalized treatment for patients with gastric cancers.

**MATERIALS AND METHODS**

**Patients**

Our study received the approval of local ethics committee. Written informed consent was obtained from each patient. The inclusion criteria were: 1) with a diagnosis of gastric cancer confirmed by endoscopic biopsy; 2) willing to undergo MR examination for preoperative assessment; 3) without absolute contraindications to MR examination and gadolinium contrast agents, such as cardiac pacemaker or defibrillator, aneurysm clip, nerve stimulator, insulin pump, cochlear implant. The exclusion criteria were: 1) receiving local or systematic treatment before MR examination or surgery; 2) without accurate HER2 scores and status based on

![Figure 2: Box plots of the (A) apparent diffusion coefficient (ADC), (B) pure diffusion coefficient (D), (C) perfusion related fraction (f) and (D) pseudo diffusion coefficient (D*) values of patients with various HER2 scores (from 0 to 3+). The line within each box represents the median value and the boxes represent data from the 25th to the 75th percentile.](image-url)
Table 3: Diagnostic performance of intravoxel incoherent motion magnetic resonance parameters in distinguishing human epidermal growth factor receptor 2 (HER2) positive gastric cancers from HER2 negative ones

| Parameters | Cut-off | Sensitivity | Specificity | AUC     | P value  |
|------------|---------|-------------|-------------|---------|----------|
| ADC        | 1.321   | 0.900       | 0.651       | 0.733   | 0.023†   |
| D          | 1.123   | 0.800       | 0.721       | 0.762   | 0.011†   |
| f          | 0.119   | 0.800       | 0.395       | 0.510   | 0.919    |
| D*         | 52.352  | 0.500       | 0.860       | 0.670   | 0.097    |

Note: ADC, apparent diffusion coefficient; D, pure diffusion coefficient; f, perfusion related fraction; D*, pseudo diffusion coefficient; AUC, area under the receiver operating characteristic (ROC) curve. The cut-off values of ADC, D and D* are in unit of $\times 10^{-3}\text{mm}^2/\text{sec}$. †P < 0.05 with ROC analysis.

Figure 3: The receiver operating characteristic (ROC) curves of the apparent diffusion coefficient (ADC) and pure diffusion coefficient (D) values in distinguishing HER2 positive gastric cancers from HER2 negative ones (area under the ROC curve, AUC = 0.733, 0.762, respectively). The reference line indicates random assignment.

Figure 4: A 63-year-old man with gastric cancer, at stage IIIC (T3N3M0). (A) Axial T2 weighted image shows a mildly hyperintense lesion located at the cardia and body of stomach (arrow) and there were enlarged lymph nodes around (curved arrow). The lesion shows hyperintense in (B) axial intravoxel incoherent motion (IVIM) magnetic resonance (MR) image (b value = 800 sec/mm²) (arrow). (C) The photomicrograph of the lesion shows poorly cohesive carcinoma with diffuse type (Hematoxylin & Eosin staining, 200 ×). (D) HER2 immunohistochemical assay shows no membrane staining is observed (score 0). The corresponding (E) apparent diffusion coefficient (ADC), (F) pure diffusion coefficient (D), (G) perfusion related fraction (F), and (H) pseudo diffusion coefficient (D*) maps show the lesion has an ADC value of $1.131 \times 10^{-3}\text{mm}^2/\text{sec}$, a D value of $0.900 \times 10^{-3}\text{mm}^2/\text{sec}$, a f value of 0.162 and a D* value of $18.876 \times 10^{-3}\text{mm}^2/\text{sec}$, respectively.
postoperative specimens; 3) with a minimum diameter of tumor less than 5 mm insufficient to contain a ROI; 4) poor MR image quality for further analysis due to motion or magnetic susceptibility artifacts.

**MR examination**

All patients underwent MR examination after fasting over 8 hours. After confirming that no contraindications (such as glaucoma, prostate hypertrophy or severe heart disease) were presented, 20 mg of scopolamine butyl bromide (1 mL: 20 mg; Chengdu NO.1 Drug Research Institute Company Limited, Chengdu, China) was injected intramuscularly to prevent gastrointestinal motility 10 minutes before MR examination. Forty-two (79.2%) of 53 patients received scopolamine butyl bromide (no adverse effects occurred within and after MR examination), whereas the remaining 11 patients (20.8%) had a contradiction to the drug regimen (9 patients) or rejected the drug (2 patients). Then all patients were asked to drink 800 ~ 1000 mL warm water 10 minutes before MR examination to fill the gastric cavity. Before MR scanning, the patients were trained to breathe smoothly.

All MR images were collected by using a clinical whole body 3.0 T scanner (Ingenia 3.0 T; Philips Medical Systems, Best, the Netherlands) with a 32 channels dStream Torso coil. Patients were placed in a supine position with head first. The respiratory sensor was carefully placed between the patient and coil. Scan duration per respiration and respiratory trigger delay were fit into the expiration phase of each patient’s respiratory cycle. MR sequences of this study included axial T2 weighted (T2W) imaging, axial IVIM MR imaging and multiphase enhanced T1 high resolution isotropic volume excitation (THRIVE) imaging.

Axial T2W images were obtained with the respiratory-triggered turbo spin-echo sequence without fat-saturation (repetition time, 1000 msec; echo time, 80 msec; matrix, 308 × 252; section thickness, 5 mm; gap, 0.5 mm; field of view, 380 × 380 mm; number of sections, 32; number of signals averaged, 2).

Axial IVIM MR imaging was performed with a respiratory-triggered single-shot spin-echo echo-planar sequence and spectral presaturation inversion recovery (SPIR) techniques (repetition time, 2628 msec; echo time, 55 msec; matrix, 116 × 100; section thickness, 5 mm; gap, 0.5 mm; field of view, 360 × 300 mm; number of sections, 20; number of signals averaged, 3). IVIM MR imaging was acquired with 9 b values (0, 25, 50, 75, 100, 150, 200, 500 and 800 sec/mm²) and the sections were enough to cover the lesions.

The THRIVE imaging with breath-holding and spectral attenuated inversion recovery (SPAIR) techniques (repetition time, 3.00 msec; echo time, 1.42 msec; matrix, 224 × 194; section thickness, 5 mm; gap, 0.5 mm; field of view, 380 × 380 mm; number of sections, 32; number of signals averaged, 1) were utilized before and 30, 60, 90 and 180 seconds after administration of 0.2 mL per kilogram of body weight gadodiamide (Omniscan 0.5 mmoL/mL; GE Healthcare, Ireland) using an automatic power injector (Medrad Spectris Solaris EP MR Injector System; One Medrad Drive Indianola, PA, US). All patients underwent MR scanning successfully without any discomfort or side effects.

**Image analyses**

All MR images were reviewed by 2 radiologists (J. H., Z. Z.) with 8 and 10 years’ experience in abdominal

![Figure 5: A 51-year-old woman with gastric cancer, at stage IIIB (T3N2M0).](image-url) (A) Axial T2 weighted image shows a mildly hyperintense lesion located at the cardia of stomach (arrow). The lesion shows hyperintense in (B) axial intravoxel incoherent motion (IVIM) magnetic resonance (MR) image (b value = 800 sec/mm²) (arrow). (C) The photomicrograph of the lesion shows poorly differentiated adenocarcinoma with mixed type (Hematoxylin & Eosin staining, 200 ×). (D) HER2 immunohistochemical assay shows complete and intense circumferential membrane staining in > 10 % of tumor cells (score 3+). The corresponding (E) apparent diffusion coefficient (ADC), (F) pure diffusion coefficient (D), (G) perfusion related fraction (f), and (H) pseudo diffusion coefficient (D*) maps show the lesion has an ADC value of $1.339 \times 10^{-3} \text{mm}^2/\text{sec}$, a D value of $1.242 \times 10^{-3} \text{mm}^2/\text{sec}$, a f value of 0.096 and a D* value of $83.519 \times 10^{-3} \text{mm}^2/\text{sec}$, respectively.
MR imaging, who were blinded to the endoscopic biopsy and postoperative pathologic findings. The IVIM sequence was loaded into a software IDL 6.3 (ITT Visual Information Solutions, Boulder, CO), and then was analyzed with both mono-exponential and bi-exponential models introduced by Le Bihan [19].

Gastric cancer lesions showed mildly hyperintense on T2W, and hyperintense on IVIM (b = 800 sec/mm²) images with remarkable contrast enhancement. For each patient, the specific slice of axial IVIM image (b = 800 sec/mm²) showing the largest area of tumor was selected. Based on the consensus of two radiologists, an oval ROI (mean area, 49.7 mm²; range, 27.2 ~ 97.8 mm²) was manually drawn as large as possible within the solid part of the lesion by referring to the corresponding images of other MR sequences. Artifacts, distortions, vessels, necrotic and hemorrhagic tissues were carefully avoided in choosing the ROIs. If the lesion showed a sandwich sign [12], the ROI was set to avoid the internal muscular layer. Then the ROI was automatically transferred into the parameter maps (ADC, D, f and D* maps, respectively) and the mean value from each ROI was obtained. The ADC value was calculated with a mono-exponential decay model: $S_D = S_0 \times \exp(-b \times \text{ADC})$, by using multiple b values. The D, f and D* values were calculated by the bi-exponential model: $S_D/S_0 = (1 - f) \times \exp(-b \times D) + f \times \exp(-b \times (D* + D))$, in which $S_0$ represents the mean signal intensity with diffusion gradient, $S_D$ represents the mean signal intensity when $b = 0$ sec/mm² [19].

**Postoperative pathological analyses**

Forty-four patients underwent curative gastrectomy (including 16 total and 28 partial gastrectomies) and 9 patients underwent palliative resection by the surgeons (M. W., H. W.) with 6 and 9 years’ experience in gastrointestinal surgery. The pathological analyses were performed by a pathologist (L. C.) with 6 years’ experience in digestive malignancy, who was blinded to MR findings and IVIM measurements. The location, histological differentiation and Lauren classification of the gastric cancers were analyzed and recorded according to the World Health Organization (WHO) classification (2010) [35]. Histopathological staging of the tumors was performed based on the TNM classification of the American Joint Committee on Cancer (AJCC, 7th edition) [36]. The mean volume of the tumors was $30617.4 \pm 29918.2$ mm³ (range, $812.5 ~ 121482.0$ mm³).

In our study, 3 patients (3/53, 5.7%) were diagnosed with distant metastasis (2 with peritoneal metastases and 1 with hepatic metastasis, respectively) postoperatively, which were not observed with conventional diagnosis preoperatively.

A specific scoring system was introduced for the HER2 assessment of the gastric cancers, which was recently reinforced in consensus panel recommendations. The scoring criteria were modified according to the study by Hofmann et al [37]. In detail, when considering HER2 protein status determination using IHC in gastric cancer resections, a patient was classified as score 3+ (IHC positive) if the membrane staining was strong complete, basolateral or lateral in > 10% of tumor cells; score 2+ (IHC equivocal) if the membrane staining was weak-to-moderate complete, basolateral or lateral in > 10% of tumor cells; score 1+ (IHC negative) if the membrane staining was faint/barely perceptible incomplete in >10% of tumor cells; and score 0 (IHC negative) if no staining was observed or the membrane staining is in < 10% of tumor cells. Equivocal cases at IHC (score 2+) were subjected to FISH analysis. At a cytogenetic level, FISH interpretation criteria were based on a HER2/CEP17 ratio ≥ 2 as a cut off to define a HER2 FISH+ test.

**Statistical analyses**

Clinicopathological features of gastric cancers with different HER2 status were compared using chi square test. IVIM parameters of gastric cancers with different HER2 scores were compared using one-way analysis of variance. And the Least-Significant-Difference method was adopted for further multiple comparisons. Partial correlation test including tumor volume was performed to analyze correlations between IVIM values and HER2 scores excluding the impact of tumor size. IVIM parameters of gastric cancers with different HER2 status were compared using independent samples t test. Diagnostic performance of IVIM parameters in distinguishing HER2 positive gastric cancers from negative ones was tested with receiver operating characteristic (ROC) analysis. All statistical analyses were performed with SPSS (version 18.0 for Microsoft Windows ×64, SPSS, US). A two-tailed P value less than 0.05 was considered statistically significant.

**ACKNOWLEDGMENTS AND FUNDING**

This work was supported by grants from National Health and Family Planning Commission of China (W201306), National Natural Science Foundation of China (81371516, 81501441 and 81601463), Natural Science Foundation of Jiangsu Province (BK20150109), Research Project of Health and Family Planning Commission of Jiangsu Province (Q201508), Key Project supported by Medical Science and technology development Foundation, Nanjing Department of Health (YKK15068) and Six Talent Peaks Project of Jiangsu Province (WSN-079).

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.
REFERENCES

1. Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014; 20:4483–4490.

2. Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. J Gastroenterol. 2010; 16:5621–5628.

3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687–697.

4. Dittrich A, Gautrey H, Browell D, Tyson-Capper A. The HER2 Signaling Network in Breast Cancer-Like a Spider in its Web. J Mammary Gland Biol Neoplasia. 2014; 19:253–270.

5. Won E, Janjigian YJ, Ilson DH. HER2 Directed Therapy for Gastric/Esophageal Cancers. Curr Treat Options Oncol. 2014; 15:395–404.

6. Ly Q, Meng Z, Yu Y, Jiang F, Guan W, Liang C, Zhou J, Lu A, Zhang G. Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. Int J Mol Sci. 2016; 17.

7. Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, Sakai Y. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013; 16:84–93.

8. Liu S, He J, Guan W, Li Q, Yu H, Zhou Z, Bao S, Zhou Z. Added value of diffusion-weighted MR imaging to T2-weighted and dynamic contrast-enhanced MR imaging in T staging of gastric cancer. Clin Imaging. 2014; 38:122–128.

9. Liu S, He J, Guan W, Li Q, Zhang X, Mao H, Yu H, Zhou Z. Preoperative T staging of gastric cancer: comparison of diffusion- and T2-weighted magnetic resonance imaging. J Comput Assist Tomogr. 2014; 38:544–550.

10. Joo I, Lee JM, Kim JH, Shin CI, Han JK, Choi BI. Prospective comparison of 3T MRI with diffusion-weighted imaging and MDCT for the preoperative TNM staging of gastric cancer. J Magn Reson Imaging. 2015; 41:814–821.

11. Shinya S, Sasaki T, Nakagawa Y, Gusszting Z, Yamamoto F, Yamashita Y. The usefulness of diffusion-weighted imaging (DWI) for the detection of gastric cancer. Hepatogastroenterology. 2007; 54:1378–1381.

12. Zhang XP, Tang L, Sun YS, Li ZY, Ji JF, Li XT, Liu YQ, Wu Q. Sandwich sign of Borrmann type 4 gastric cancer on diffusion-weighted magnetic resonance imaging. Eur J Radiol. 2012; 81:2481–2486.

13. Tang L, Sun YS, Li ZY, Cao K, Zhang XY, Li XT, Ji JF. Diffusion-weighted magnetic resonance imaging in the depiction of gastric cancer: initial experience. Abdom Radiol. 2016; 41:2–9.

14. Liu S, Guan W, Wang H, Pan L, Zhou Z, Yu H, Liu T, Yang X, He J, Zhou Z. Apparent diffusion coefficient value of gastric cancer by diffusion-weighted imaging: correlations with the histological differentiation and Lauren classification. Eur J Radiol. 2014; 83:2122–2128.

15. Zhang Y, Chen J, Liu S, Shi H, Guan W, Ji C, Guo T, Zheng H, Guan Y, Ge Y, He J, Zhou Z, Yang X, et al. Assessment of histological differentiation in gastric cancers using whole-volume histogram analysis of apparent diffusion coefficient maps. J Magn Reson. 2017; 45:440–449.

16. Liu S, Wang H, Guan W, Pan L, Zhou Z, Yu H, Liu T, Yang X, He J, Zhou Z. Preoperative apparent diffusion coefficient value of gastric cancer by diffusion-weighted imaging: Correlations with postoperative TNM staging. J Magn Reson Imaging. 2015; 42:837–843.

17. He J, Shi H, Zhou Z, Chen J, Guan W, Wang H, Yu H, Liu S, Zhou Z, Yang X, Liu T. Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study. BMC cancer. 2015; 15:749.

18. Mazaheri Y, Afaq A, Rowe DB, Lu Y, Shukla-Dave A, Grover J. Diffusion-weighted magnetic resonance imaging of the prostate: improved robustness with stretched exponential modeling. J Comput Assist Tomogr. 2012; 36:695–703.

19. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988; 168:497–505.

20. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoery HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammod DA, Rustin GJ, Taouli B, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009; 11:102–125.

21. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986; 161:401–407.

22. Granata V, Fusco R, Catalano O, Guarino B, Granata F, Tatangelo F, Avallone A, Piccirillo M, Palai R, Izzo F, Petrillo A. Intraoperative motion detection with intraoperative diffusion- weighted imaging (IVIM) in diffusion-weighted imaging (DWI) for Hepatocellular carcinoma: correlation with histologic grade. Oncotarget. 2016; 7:79357–79364. doi: 10.18632/oncotarget.12689.

23. Kim Y, Ko K, Kim D, Min C, Kim SG, Joo J, Park B. Intravoxel incoherent motion diffusion-weighted MR imaging of breast cancer: association with histopathological features and subtypes. Br J Radiol. 2016; 89:20160140.

24. Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, Lopez-Sanchez RJ, Price T, Gladkov O, Stoss O, Hill J, Ng V, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015; 18:476–484.
25. Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013; 8:76.

26. Huang D, Lu N, Fan Q, Sheng W, Bu H, Jin X, Li G, Liu Y, Li X, Sun W, Zhang H, Li X, Zhou Z, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PloS one. 2013; 8:e80290.

27. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. J Gastroenterol. 2013; 19:2171–2178.

28. Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014; 17:34–42.

29. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005; 16:273–278.

30. Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz ALT. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin. 2015; 141:1343–1351.

31. Woo S, Lee JM, Yoon JH, Joo I, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade. Radiology. 2014; 270:758–767.

32. Ma L, Xu X, Zhang M, Zheng S, Zhang B, Zhang W, Wang P. Dynamic contrast-enhanced MRI of gastric cancer: Correlations of the pharmacokinetic parameters with histological type, Lauren classification, and angiogenesis. Magn Reson Imaging. 2017; 37:27–32.

33. Valerio M, Zini C, Fierro D, Giura F, Colarieti A, Giuliani A, Laghi A, Catalano C, Panebianco V. 3T multiparametric MRI of the prostate: Does intravoxel incoherent motion diffusion imaging have a role in the detection and stratification of prostate cancer in the peripheral zone? Eur J Radiol. 2016; 85:790–794.

34. Federau C, Hagmann P, Maeder P, Muller M, Meuli R, Stuber M, O’Brien K. Dependence of brain intravoxel incoherent motion perfusion parameters on the cardiac cycle. PloS one. 2013; 8:e72856.

35. Lauwers GY, Franceschi S, Carneiro F, et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (editors). WHO classification of tumors of the digestive system. Lyon, France: IARC Press; 2010; pp 225–227.

36. Edge SB, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York (NY): Springer; 2010.

37. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52:797–805.